Development and Validation of a Protein-based Signature for the Detection of Ovarian Cancer

Clinics in Laboratory Medicine

Volumn 29, Issue 1, 2009, Pages 47-55

  Kim, Kyongjin ^a   Visintin, Irene ^a   Alvero, Ayesha B ^a   Mor, Gil ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Early detection; Insulin like Growth Factor II (IGF II) multiplex; Leptin; Macrophage Inhibitory Factor (MIF); Osteopontin; Ovarian cancer; Prolactin

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; LEPTIN; MACROPHAGE MIGRATION INHIBITION FACTOR; OSTEOPONTIN; PROLACTIN; SOMATOMEDIN B; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER RISK; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLEX BEAD ARRAY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE;

DATA INTERPRETATION, STATISTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 64649105107     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2009.02.001     Document Type: Review

References (35)

1. Permuth-Wey J., and Sellers T.A. Epidemiology of ovarian cancer. Methods Mol Biol 472 (2009) 413-437
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2006) 106-130
3. Schwartz P.E. Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res 107 (2002) 99-118
4. Berchuck A., Elbendary A., Havrilesky L., et al. Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1 3 (1994) 181-190
5. Goff B.A., and Muntz H.G. Screening and early diagnosis of ovarian cancer. Women's Health in Primary Care 8 6 (2005) 262-268
6. Miller B.A., Chu K.C., Hankey B.F., et al. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S. Cancer Causes Control 19 3 (2008) 227-256
7. Espey D.K., Wu X.C., Swan J., et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 110 10 (2007) 2119-2152
8. Mutch D. Surgical manegement of ovarian cancer. Semin Oncol 29 (2002) 3-8
9. Permuth-Wey J., Boulware D., Valkov N., et al. Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer. Cancer Epidemiol Biomarkers Prev 18 1 (2009) 28-34
10. Nick A.M., and Sood A.K. The ROC 'n' role of the multiplex assay for early detection of ovarian cancer. Nat Clin Pract Oncol 5 10 (2008) 568-569
11. Berger R.P., Ta'asan S., Rand A., et al. Multiplex assessment of serum biomarker concentrations in well-appearing children with inflicted traumatic brain injury. Pediatr Res 65 (2008) 97-102
12. Gagnon A., and Ye B. Discovery and application of protein biomarkers for ovarian cancer. Curr Opin Obstet Gynecol 20 1 (2008) 9-13
13. Bast Jr. R.C., Badgwell D., Lu Z., et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15 Suppl 3 (2005) 274-281
14. Wu B., Abbott T., Fishman D., et al. Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data. Bioinformatics 19 13 (2003) 1636-1643
15. Bast Jr. R.C., Brewer M., Zou C., et al. Prevention and early detection of ovarian cancer: mission impossible?. Recent Results Cancer Res 174 (2007) 91-100
16. Petricoin E.F., Ardekani A.M., Hitt B.A., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 9306 (2002) 572-577
17. Chang J., Powles T.J., Allred D.C., et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17 10 (1999) 3058-3063
18. Woolas R.P., Xu F.J., Jacobs I.J., et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 85 21 (1993) 1748-1751
19. Gorelik E., Landsittel D.P., Marrangoni A.M., et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 14 4 (2005) 981-987
20. Mor G., Visintin I., Lai Y., et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102 21 (2005) 7677-7682
21. Vignali D.A. Multiplexed particle-based flow cytometric assays. J Immunol Methods 243 1-2 (2000) 243-255
22. Anderson N.L. The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol Cell Proteomics 4 10 (2005) 1441-1444
23. Agarwal R., Alvero A., Visintin I., et al. Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol 196 4 (2007) 348.e1-348.e5
24. Visintin I., Feng Z., Longton G., et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14 4 (2008) 1065-1072
25. Giudice L.C. Insulin-like growth factor family in Graafian follicle development and function. J Soc Gynecol Investig 8 1 Suppl Proceedings (2001) S26-S29
26. Kaipia A., and Hsueh A.J. Regulation of ovarian follicle atresia. Annu Rev Physiol 59 (1997) 349-363
27. Grosdemouge I., Bachelot A., Lucas A., et al. Effects of deletion of the prolactin receptor on ovarian gene expression. Reprod Biol Endocrinol (2003) 1-12
28. Bachelot A., and Binart N. Corpus luteum development: lessons from genetic models in mice. Curr Top Dev Biol 68 (2005) 49-84
29. Popovic V., and Casanueva F.F. Leptin, nutrition and reproduction: new insights. Hormones (Athens) 1 4 (2002) 204-217
30. Brakora K.A., Lee H., Yusuf R., et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 93 2 (2004) 361-365
31. Chambers A.F., and Vanderhyden B.C. Ovarian cancer biomarkers in urine. Clin Cancer Res 12 2 (2006) 323-327
32. Morand E.F., Leech M., Weedon H., et al. Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology (Oxford) 41 5 (2002) 558-562
33. Mitchell R.A., Liao H., Chesney J., et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A 99 1 (2002) 345-350
34. Piver M.S., Jishi M.F., Tsukada Y., et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71 9 (1993) 2751-2755
35. Finch A., Beiner M., Lubinski J., et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296 2 (2006) 185-192